Literature DB >> 26232774

Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Joseph G Taylor1, John G Gribben2.   

Abstract

Innate and adaptive immune cells within the microenvironment identify and eliminate cells displaying signs of malignant potential. Immunosurveillance effector Natural Killer (NK) cells and Cytotoxic T Lymphocytes (CTL) identify malignant cells through germline receptors such as NKG2D and in the case of CTLs, presentation of antigen through the T cell receptor. Manipulation of immunosurveillance through altered tumor-identifying ligand expression or secretion, resistance to cytotoxicity, or compromised cytotoxic cell activity through immune tolerance mechanisms all contribute to failure of these systems to prevent cancer development. This review examines the diverse mechanisms by which alterations in the immune microenvironment can promote lymphomagenesis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anergy; CD8; Cytotoxic; IL-10; Immunosurveillance; Lymphomagenesis; Microenvironment; NKG2D; Natural killer; PD-1; Regulatory; TGFβ; Tumorigenesis

Mesh:

Year:  2015        PMID: 26232774      PMCID: PMC4592463          DOI: 10.1016/j.semcancer.2015.07.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  131 in total

Review 1.  Inherited defects in lymphocyte cytotoxic activity.

Authors:  Jana Pachlopnik Schmid; Jana P Schmid; Marjorie Côte; Mickaël M Ménager; Agathe Burgess; Nadine Nehme; Gaël Ménasché; Alain Fischer; Geneviève de Saint Basile
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.

Authors:  Ahmed M L Bedewy; Maha M Adel Elgammal; Magdy M L Bedewy; Shereen M El-Maghraby
Journal:  Ann Hematol       Date:  2013-05-08       Impact factor: 3.673

Review 3.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

4.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

5.  MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction.

Authors:  Anne Nolting; Anne-Sophie Dugast; Suzannah Rihn; Rutger Luteijn; Mary F Carrington; Katherine Kane; Stephanie Jost; Ildiko Toth; Ellen Nagami; Gerd Faetkenheuer; Pia Hartmann; Marcus Altfeld; Galit Alter
Journal:  Virology       Date:  2010-07-29       Impact factor: 3.616

Review 6.  Marginal zone lymphomas and infectious agents.

Authors:  Andrés J M Ferreri; Silvia Govi; Maurilio Ponzoni
Journal:  Semin Cancer Biol       Date:  2013-09-30       Impact factor: 15.707

7.  Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.

Authors:  Norman Nausch; Ioanna E Galani; Eva Schlecker; Adelheid Cerwenka
Journal:  Blood       Date:  2008-08-27       Impact factor: 22.113

8.  Decreased tumor surveillance in perforin-deficient mice.

Authors:  M E van den Broek; D Kägi; F Ossendorp; R Toes; S Vamvakas; W K Lutz; C J Melief; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

9.  T cell-independent development and induction of somatic hypermutation in human IgM+ IgD+ CD27+ B cells.

Authors:  Ferenc A Scheeren; Maho Nagasawa; Kees Weijer; Tom Cupedo; Jörg Kirberg; Nicolas Legrand; Hergen Spits
Journal:  J Exp Med       Date:  2008-08-11       Impact factor: 14.307

10.  Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study.

Authors:  Ji-Young Choe; Ji Yun Yun; Yoon Kyoung Jeon; Se Hoon Kim; Gyeongsin Park; Joo Ryoung Huh; Sohee Oh; Ji Eun Kim
Journal:  BMC Cancer       Date:  2014-05-15       Impact factor: 4.430

View more
  12 in total

1.  The incidence and mortality trends of bone lymphoma in the United States: An analysis of the Surveillance, Epidemiology, and End Results database.

Authors:  Daoliang Xu; Ben Wang; Lijie Chen; Huawei Zhang; Xiangyang Wang; Jiaoxiang Chen
Journal:  J Bone Oncol       Date:  2020-07-17       Impact factor: 4.072

Review 2.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

3.  Loss of Setd4 delays radiation-induced thymic lymphoma in mice.

Authors:  Xing Feng; Huimei Lu; Jingyin Yue; Neta Schneider; Jingmei Liu; Lisa K Denzin; Chang S Chan; Subhajyoti De; Zhiyuan Shen
Journal:  DNA Repair (Amst)       Date:  2019-11-25

4.  The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.

Authors:  Jiangzhou Peng; Zigang Yu; Lei Xue; Jiabin Wang; Jun Li; Degang Liu; Qiang Yang; Yihui Lin
Journal:  Mol Med Rep       Date:  2018-02-13       Impact factor: 2.952

Review 5.  Role of Mast Cells in Shaping the Tumor Microenvironment.

Authors:  Daniel Elieh Ali Komi; Frank A Redegeld
Journal:  Clin Rev Allergy Immunol       Date:  2020-06       Impact factor: 8.667

Review 6.  Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.

Authors:  Stefania Cuzzubbo; Sara Mangsbo; Divya Nagarajan; Kinana Habra; Alan Graham Pockley; Stephanie E B McArdle
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

7.  Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact.

Authors:  Melina Cohen; Aldana G Vistarop; Fuad Huaman; Marina Narbaitz; Fernanda Metrebian; Elena De Matteo; María V Preciado; Paola A Chabay
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

Review 8.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

9.  A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.

Authors:  Ana Victoria Casadesús; Claire Deligne; Béré Kadjdiatou Diallo; Katya Sosa; Nathalie Josseaume; Circe Mesa; Kalet León; Tays Hernández; Jean-Luc Teillaud
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110

10.  Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database.

Authors:  Xuejiao Yin; Aoshuang Xu; Fengjuan Fan; Zhenli Huang; Qianwen Cheng; Lu Zhang; Chunyan Sun; Yu Hu
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.